In order to evaluate the clinical relevance of the xenograft models for metabolism studies, human breast cancer biopsies from the corresponding molecular subtypes were analyzed using identical methods.
The pedigrees of these eleven families are shown in Figure 4, along with corresponding molecular subtypes, BRCA1 methylation status and prediction results obtained by the basal BRCA1-classifier and the lumB BRCA2-classifer.
The distribution of molecular subtypes in primary tumours and corresponding lymph node metastases were compared, and related to 5-year distant disease-free survival (DDFS).
Breast cancer cell lines corresponding to the breast molecular subtypes: Basal-like (HCC70), Luminal (T47D) and HER2 amplified (SKBR3) cells were spiked into normal donor blood collected into EDTA tubes, using donor blood alone as a control.
The classifications of primary breast cancer tumours and corresponding lymph node metastases by molecular subtypes were compared using the exact McNemar-Bowker test of symmetry.
Next, we computed the correlations of these 757 sample-specific expression levels with the corresponding expression levels of the four molecular subtypes.
Molecular subtypes are associated with various clinical outcomes, and treatment strategies are tailored to corresponding groups of patients (e.g. anti-ERBB2 therapies for patients with ERBB2-like tumours or hormone therapy for patients with luminal tumours).
To determine molecular subtypes, RNA extracted from 22 specimens of fresh frozen human glioma using TRIzol and from the corresponding GC lines in the same manner as described above, was used in a custom-made assay by NanoString Technology.
Next, we sought to identify associations with tumour molecular subtypes, and as an initial analysis chose the molecular subtypes of breast cancer, owing to both the well-defined subtypes and the relatively large number of cases available for each subtype.
Breast cancer is commonly classified into intrinsic molecular subtypes.
